A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Irosustat
Sponsor: Imperial College London
Collaborators: National Institute for Health Research, United Kingdom|Ipsen|Imperial College Healthcare NHS Trust|Guy's and St Thomas' NHS Foundation Trust|University of Southern California|QPS Netherlands B.V.